DNA Script, a life sciences tech firm specialising in Enzymatic DNA Synthesis (EDS), has announced that it has secured €176.8M ($200m) in a Series C round of funding. With this latest financing, DNA Script has raised a total of €278.5M ($315M) to date and will accelerate the commercial launch of its DNA printing technology.
The completion of the Series C financing builds upon a €145.9M tranche announced by the company last year. The proceeds from this funding will help DNA Script commercialise its SYNTAX Platform based on its proprietary EDS technology. The SYNTAX is like a 3D printer for printing DNA using enzymatic DNA printing technology.